Overview

Study To Assess Long Term Safety Of Pazopanib

Status:
Completed

Trial end date:
2018-03-08

Target enrollment:

Participant gender:

Summary

This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Lapatinib